This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    01/03/09

    Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.

    To determine the prevalence of methylphenidate, dexamfetamine and atomoxetine prescribing and treatment discontinuation in adolescents and young adults.

    • Source: The British Journal of Psychiatry
    Journals
    Journal
    13/06/14

    Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature.

    To raise awareness of attention-deficit/hyperactivity disorder (ADHD) as an underdiagnosed, undertreated, often comorbid, and debilitating condition in adults.

    • Source: The Primary Care Companion for CNS Disorders
    Journals
    Journal
    30/04/16

    Diagnostic accuracy of a brief screening tool for attention deficit hyperactivity disorder in UK prison inmates.

    Attention deficit hyperactivity disorder (ADHD) is overrepresented in prison, making it imperative to identify a screening tool that can be quickly applied to efficiently detect the disorder.

    • Source: Psychological Medicine
    Journals
    Journal
    01/02/06

    The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.

    This study examined the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood.

    • Source: Psychological Medicine
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/01/17

    Phase III study (SEP360-301) evaluating dasotraline in adults with attention deficit hyperactivity disorder fails to meet primary endpoint- Sunovion

    Sunovion announced that the Phase III study (SEP360-301) evaluating dasotraline in adults ages 18 to 55 years with attention deficit...

    Blue test tubes arranged in a line, disappearing into the background
    News
    22/10/24

    FDA approves Qelbree for attention-deficit hyperactivity disorder in pediatric patients.- Supernus Pharmaceuticals

    Supernus Pharmaceuticals announced that the FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.

    Journals
    Journal
    01/01/14

    Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

    Treatment options for adults with attention deficit hyperactivity disorder (ADHD) are limited. The study was conducted to confirm the clinically effective and safe dose of methylphenidate hydrochloride...

    • Source: Advances in Therapy
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/09/17

    Phase III study of Intuniv (guanfacine hydrochloride prolonged release) meets primary endpoint in adults with attention deficit hyperactivity disorder.- Shire + Shionogi.

    Shire and Shionogi announced that a Phase III study evaluating Intuniv (guanfacine hydrochloride prolonged release) in adult patients with attention...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/11/15

    Monarch eTNS Nerve Stimulation System receives EU CE Mark approval for Attention-Deficit/Hyperactivity Disorder- NeuroSigma

    NeuroSigma has received CE Mark approval for its Monarch eTNS System as treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and...

    Guidelines
    Guideline
    01/07/24

    Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period

    Managing ADHD during pregnancy and postpartum is crucial due to the increased challenges and risks. This guideline offers best practices for individualized treatment, psychoeducation, and safe pharmacotherapy.

    • Source: American Journal of Obstetrics & Gynecology
    See more